Claims for Patent: 9,731,033

Summary for Patent: 9,731,033

Title:	Methods and compositions relating to improved lentiviral vectors and their applications
Abstract:	The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1.alpha. promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
Inventor(s):	Trono; Didier (Vufflens-le-Chateau, CH), Salmon; Patrick (Arenthon, FR)
Assignee:	Research Development Foundation (Carson City, NV)
Application Number:	15/263,027
Patent Claims:	1. A self-inactivating recombinant lentiviral vector comprising: (a) an expression cassette comprising a transgene positioned under the control of a promoter, other than a CMV promoter, that is active to promote detectable transcription of the transgene at a signal-to-noise ratio of between about 10 and about 200 in a human T cell; and (b) an LTR region that has reduced promoter activity relative to wild-type LTR. 2. The vector of claim 1, further defined as incapable of reconstituting a wild-type lentivirus through recombination. 3. The vector of claim 2, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 40 and about 200. 4. The vector of claim 3, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 150 and about 200. 5. The vector of claim 3, wherein the promoter is an EF1-.alpha. promoter, a PGK promoter, a gp91hox promoter, a MEW class II promoter, a clotting Factor IX promoter, a clotting Factor V111 promoter, an insulin promoter, a PDX1 promoter, a CD11 promoter, a CD4 promoter, a CD2 promoter or a gp47 promoter. 6. The vector of claim 5, wherein the transgene is positioned under the control of the EF1-.alpha. promoter. 7. The vector of claim 5, wherein the transgene is positioned under the control of the PGK promoter. 8. The vector of claim 1, wherein the transgene is erythropoietin, an interleukin, a colony-stimulating factor, integrin .alpha.IIb.beta., a multidrug resistance gene, gp91hox, gp 47, an antiviral gene, a gene coding for blood coagulation factor VIII, a gene coding for blood coagulation factor IX, a T cell antigen receptor, a B cell antigen receptor, a single chain antibodies (ScFv), TNF, gamma interferon, CTLA4, B7, Melana, MAGE. 9. The vector of claim 8, wherein the transgene is gp91hox. 10. The vector of claim 8, wherein the transgene is gp 47. 11. The vector of claim 8, wherein the transgene is Interleukin-2. 12. The vector of claim 8, wherein the transgene is Interleukin-12. 13. The vector of claim 8, wherein the transgene is a gene coding for blood coagulation factor VIII. 14. The vector of claim 8, wherein the transgene is a gene coding for blood coagulation factor IX. 15. The vector of claim 1, further comprising a posttranscriptional regulatory sequence positioned to promote the expression of the transgene. 16. The vector of claim 15, wherein the posttranscriptional regulatory sequence is an intron positioned within the expression cassette. 17. The vector of claim 16, wherein the intron is positioned in an orientation opposite the vector genomic transcript. 18. The vector of claim 15, wherein the posttranscriptional regulatory sequence is a posttranscriptional regulatory element. 19. The vector of claim 18, wherein the posttranscriptional regulatory element is woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). 20. The vector of claim 18, wherein the posttranscriptional regulatory element is hepatitis B virus posttranscriptional regulatory element (HPRE). 21. The vector of claim 1, wherein the LTR region has been rendered substantially transcriptionally inactive by virtue of deletions in the U3 region of the 3' LTR. 22. A host cell transduced with a vector in accordance with claim 1. 23. The transduced host cell of claim 22, wherein the cell is a virus producer cell. 24. The transduced host cell of claim 23, wherein the producer cell is a 293T cell. 25. The host cell of claim 22, wherein the cell is a human hematopoietic progenitor cell. 26. A self-inactivating recombinant lentiviral vector comprising: (a) an expression cassette comprising a transgene positioned under the control of an EF1-.alpha. promoter that is active to promote detectable transcription of the transgene in a human T cell at a signal-to-noise ratio of between about 150 and about 200; and (b) an LTR region that has been rendered substantially transcriptionally inactive by virtue of deletions in the U3 region of the 3' LTR. 27. A method for transducing a human T cell comprising contacting a population of human T cells with a vector in accordance with claim 1 under conditions to effect the transduction of a human T cell in said population by said vector. 28. The method of claim 27, wherein the T cell in transduced in vivo. 29. The method of claim 27, wherein the T cell is transduced in vitro. 30. The method of claim 27, wherein the transduced T cell is infused into a human subject. 31. The self-inactivating recombinant vector of claim 1, wherein the transgene encodes a T cell antigen receptor. 32. The self-inactivating recombinant vector of claim 26, wherein the transgene encodes a T cell antigen receptor. 33. The self-inactivating recombinant vector of claim 1, wherein the transgene encodes a T cell antigen receptor in combination with an scFv. 34. The self-inactivating recombinant vector of claim 26, wherein the transgene encodes a T cell antigen receptor in combination with an scFv. 35. The self-inactivating recombinant vector of claim 1, wherein the transgene encodes an scFv. 36. The self-inactivating recombinant vector of claim 26, wherein the transgene encodes an scFv.

Details for Patent 9,731,033

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-11-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-11-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-11-13